A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada

Substance Abuse: Treatment, Prevention, and Policy

Volumn 8, Issue 1, 2013, Pages

  Jozaghi, Ehsan ^a   Reid, Andrew A ^a   Andresen, Martin A ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Cost benefit; Cost effectiveness; Harm reduction; Supervised injection facility

Indexed keywords

ARTICLE; CANADA; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREVENTIVE HEALTH SERVICE; STATISTICAL MODEL; STATISTICS;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEPATITIS C; HIV INFECTIONS; HUMANS; MODELS, STATISTICAL; NEEDLE-EXCHANGE PROGRAMS; QUEBEC;

EID: 84880378842     PISSN: None     EISSN: 1747597X     Source Type: Journal    
DOI: 10.1186/1747-597X-8-25     Document Type: Article

References (41)

1. Mathers BM, Degenhardt L, Buccello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ 2013, 91:102-123. 10.2471/BLT.12.108282, 3605003, 23554523.
2. World Health Organization HIV/AIDS: Injecting drug use 2013, [http://www.who.int/hiv/topics/idu/en/index.html], World Health Organization.
3. Rehm J, Ballunas D, Brochu S, Fischer B, Gnam W, Patra J, Popova S, Sarnocinska-Hart A, Taylor B. The Costs of Substance Abuse in Canada 2002: Highlights 2006, Ottawa, ON: Canadian Centre on Substance Abuse.
4. Canadian Centre on Substance Abuse Injection Drug Users Overview 2011, http://www.ccsa.ca/Eng/Topics/Populations/IDU/Pages/InjectionDrugUsersOverview.aspx, Canadian Centre on Substance Abuse.
5. Archibald CP, Jayaraman GC, Major C, Patrick DM, Houston SM, Sutherland D. Estimating the size of hard-to-reach populations: A novel method using HIV testing data compared to other methods. AIDS 2001, 15:S41-S48.
6. Roy E, Arruda N, Vaillancourt E, Boivin J, Morissette C, Leclerc P, et al. Drug use patterns in the presence of crack in downtown Montreal. Drug Alcohol Rev 2012, 31:72-80. 10.1111/j.1465-3362.2011.00299.x, 3136624, 21426421.
7. Morissette C, Cox J, De P, Tremblay C, Roy E, Allard R, et al. Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injection population: Implications for HIV and hepatitis C prevention. Int J Drug Policy 2007, 18:204-212. 10.1016/j.drugpo.2006.08.004, 17689367.
8. De P, Cox J, Boivin JF, Platt RW, Jolly AM, Alexander PE. HIV and HCV discordant injecting partners and their association to drug equipment sharing. Scand J Infect Dis 2007, 41:206-214.
9. Bruneau J, Daniel M, Kestens Y, Zang G, Généreux M. Association between HIV-related injection behavior and distance to and patterns of utilisation of syringe-supply programmes. J Epidemiol Community Health 2008, 62:804-810. 10.1136/jech.2007.064154, 18701731.
10. Jozaghi E. The science versus the politics: The need for supervised injection facilities in Montreal, Canada. Int J Drug Policy 2012, 23:420-421. 10.1016/j.drugpo.2012.06.003, 22818890.
11. Andresen MA, Jozaghi E. The point of diminishing returns: an examination of expanding Vancouver's Insite. Urban Studies 2012, 49(16):3531-3544.
12. CTVNews.ca Staff CMA 'deeply concerned' about tighter rules for safe injection sites 2013, http://www.ctvnews.ca/health/cma-deeply-concerned-about-tighter-rules-for-safe-injection-sites-1.1313766, CTVNews.ca Staff.
13. O'Neil P. Vancouver's supervised injection site will survive new federal rules, supporter say 2013, http://www.vancouversun.com/health/Vancouver+supervised+injection+site+will+survive+federal/8488985/story.html.
14. Semaan S, Fleming P, Worrell C, Stolp H, Baack B, Miller M. Potential role of safer injection facilities in reducing HIV and Hepatitis C infections and overdose mortality in the United States. Drug Alcohol Depend 2011, 118:100-110. 10.1016/j.drugalcdep.2011.03.006, 21515001.
15. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection facility. Can Med Ass J 2008, 179(11):1143-1151.
16. Pinkerton SD. Is Vancouver Canada's supervised injection facility cost-saving?. Addiction 2010, 105:1429-1436. 10.1111/j.1360-0443.2010.02977.x, 20653622.
17. Andresen MA, Boyd NT. A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility. Int J Drug Policy 2010, 21:70-76. 10.1016/j.drugpo.2009.03.004, 19423324.
18. Jacobs P, Calder P, Taylor M, Houston S, Saunders LD, Albert T. Cost effectiveness of streetworks' needle exchange program of Edmonton. Can J Public Health 1999, 90(3):168-171.
19. Généreux M, Bruneau J, Daneil M. Association between neighborhood socioeconomic characteristics and high-risk injection behavior amongst injection drug users living in inner and othe city areas in Montreal, Canada. Int J Drug Policy 2010, 21:49-55. 10.1016/j.drugpo.2009.01.004, 19250813.
20. Broadhead RS, Kerr TH, Grund JP, Altice FL. Safer injection facilities in North America: Their place in public policies and health initiatives. J Drug Issues 2002, 32:329-355.
21. Kaplan EH, O'Keefe E. Let the needles do the talking! Evaluating the New Haven needle exchange. Interfaces 1993, 23:7-26.
22. Gore SM, Bird AG. Study size and documentation to detect injection-related hepatitis C in prison. Quantitative J Med 1998, 91:353-357.
23. Des Jarlais DC, Arasteh K, Hagan H. Evaluating Vancouver's supervised injection facility: Data and dollars, symbols and ethics. Can Med Assoc J 2008, 179(11):1105-1106.
24. Gold M, Gafni A, Nelligan P, Millson P. Needle exchange programs: An economic evaluation of a local experience. Can Med Assoc J 1997, 157(3):255-262.
25. Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL, Cloud GA, et al. Distribution of health care expenditure for HIV-infected patients. Clin Infect Dis 2006, 42:1003-1010. 10.1086/500453, 16511767.
26. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:55-61.
27. Pinkerton SD, Holtgrave DR. Assessing the cost-effectiveness of HIV prevention interventions: a primer. Handbook of Economic Evaluation of HIV Programs 1998, 33-43. New York: Plenum, Holtgrave DR.
28. Werb D, Wood E, Kerr T, Hershfield N, Palmer RWH, Remis RS. Treatment costs of hepatitis C infection among injection drug users in Canada, 2006-2026. Int J Drug Policy 2011, 22:70-76. 10.1016/j.drugpo.2010.09.006, 21051212.
29. Albert T, Williams G, Legowski B, Remis R. The economic burden of HIV/AIDS in Canada 1998, Ottawa, ON: Canadian Policy Research Networks.
30. Pinkerton SD. How many HIV infections are prevented by Vancouver Canada's supervised injection facility?. Int J Drug Policy 2011, 22:179-183. 10.1016/j.drugpo.2011.03.003, 21450450.
31. Krajden M, Kuo M, Zagorski AM, Yu A, Krahn M. Health care costs associated with hepatitis C: A longitudinal cohort study. Canadian J Gastroenterol 2010, 24(12):717-726.
32. Martin N, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et al. Cost-effectiveness of Hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 2012, 55(1):49-57. 10.1002/hep.24656, 21898506.
33. National Centre in HIV Epidemiology and Clinical Research Epidemiological and economical impact of potential increased hepatitis C treatment uptake in Australia 2010, Sydney: The University of New South Wales, National Centre in HIV Epidemiology and Clinical Research.
34. Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18(Suppl 1):S133-S138.
35. Laufer FN. Cost-effectiveness of syringe exchange as an HIV prevention strategy. J Acquir Immune Defic Syndr 2001, 28:273-278.
36. McClean ME. Vancouver drug use epidemiology-2001: Vancouver and BC site report for the Canadian community epidemiology network on drug use 2002, Vancouver, BC: Vancouver-Richmond Health Board.
37. Health Canada Vancouver's Insite service and other supervised injection sites: What has been learned from research? Final report of the export advisory committee 2008, Ottawa (ON): Health Canada, Health Canada.
38. Canada Newswire A slightly softer rental market in the Montreal metropolitan area 2006, [http://search.proquest.com/docview/453170769?accountid=13800], Canada Newswire.
39. Nurses Union Overview of key nursing contract provisions 2011, http://www.nursesunions.ca/sites/default/files/2011.07.contract_comparison.e.pdf, Nurses Union.
40. Kerr T, Tyndall M, Li K, Montaner J, Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet 2005, 366:316-318. 10.1016/S0140-6736(05)66475-6, 16039335.
41. MSIC Evaluation Committee Final report on the evaluation of the Sydney Medically Supervised Injection Center 2003, Sydney (Australia): Authors, MSIC Evaluation Committee.